In contrast, the number of CD8+TILs evaluated by focusing on hot spots may not reflect the antitumor immune status in the whole tumor, because observers evaluated the density of CD8+TILs in extremely small areas (i.e. high-power fields) in the current study. The gene discussed is CD8A; the disease is neoplasm.